Cabaletta Bio CABA 深 滬
已收盤 04-02 16:00:00 美东时间
2.96
+0.280
+10.45%
華盛通- 最 高2.98
- 今 開2.62
- 成交量 210.68万股
- 最 低 2.62
- 昨 收 2.68
- 總市值 3.30亿
- 52周最高 3.78
- 市盈率 靜 --
- 換手率 1.89%
- 52周最低 1.06
- 委 比 39.44%
- 總股本 1.11亿
- 歷史最高 26.35
- 量 比 1.05
- 振 幅 13.43%
- 歷史最低 0.59
- 每 手 1
- 風險率 0.61%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股机会日报 | 特朗普再放豪言！正与伊朗谈判，并收到伊方“大礼”；特斯拉机器人再迎新进展！马斯克称有望明年实现量产
特朗普再放豪言！正与伊朗谈判，并收到伊方“大礼”；特斯拉机器人再迎新进展！马斯克称有望明年实现量产；拼多多盘前涨超4%，Q4营收1239亿元略超预期>>
03-25 20:25
美股大行评级 | 潜在涨幅499.25%！Cabaletta Bio获Guggenheim升目标价至16美元，维持"买入"评级
今日重点评级关注：Guggenheim：维持Cabaletta Bio"买入"评级，目标价从15美元升至16美元；HC Wainwright & Co.：维持Palvella Therapeutics"买入"评级，目标价从255美元升至270美元
03-25 10:31
Cabaletta Bio Updates Rese-cel Programs and Financial Outlook
Cabaletta Bio ( ($CABA) ) has provided an announcement. On March 23, 2026, Caba...
03-23 19:57
Cabaletta Bio Q4 EPS $(0.40) Beats $(0.47) Estimate
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.47) by 13.98 percent. This is a 38.46 percent increase over losses of $(0.65) per share from the
03-23 19:35
Cabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases
Cabaletta Bio Publishes Corporate Presentation on Rese-cel CD19-CAR T Development for Autoimmune Diseases Cabaletta Bio outlined development of rese-cel (CABA-201), an autologous 4-1BB CD19-CAR T program for autoimmune diseases, and said a pivotal myositis study is enrolling with a planned 2027 BLA
03-23 19:34
Cabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26
Cabaletta Bio expects initial RESET-SLE no-preconditioning rese-cel data in 1H26 Cabaletta reported that its no-preconditioning clinical program for rese-cel is enrolling in the RESET-SLE and RESET-PV trials. Initial data from RESET-SLE in patients treated with a single weight-based dose of rese-cel
03-23 19:33
Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Cabaletta Bio reported on the progress of rese-cel, an investigational CAR T cell therapy targeting autoimmune diseases. Key updates include enrollment in a registrational dermatomyositis cohort, initial clinical experience with automated manufacturing, and advancements in no-preconditioning programs in lupus and pemphigus vulgaris. The company anticipates submitting a BLA for rese-cel in myositis in 2027 and presenting complete Phase 1/2 data ac...
03-23 11:30
当自免CAR-T来到兑现前夜
文 | 氨基观察 如果说过去十年，CAR-T疗法是肿瘤学领域的一场“神迹”，那么现在，这场神迹正跨越边界，向另一片广阔的领域蔓延—— 从最早的难治性红斑狼疮...
03-03 10:47
Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference
Cabaletta Bio, a late-stage biotech company focused on developing curative cell therapies for autoimmune diseases, will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. The presentation will be available live and via replay on their website. The company's CABA™ platform focuses on engineered T cell therapies, with its lead CARTA strategy prioritizing rese-cel, an investigational CD19-CAR T cell t...
02-24 13:00
美股牛股 | 智能家居公司SKYX大涨25%，推出天花板风扇创新产品；OPRT大涨25%
智能家居公司SKYX大涨25%，推出天花板风扇创新产品，管理层对其预期乐观；OPRT大涨25%，公司Q4及全年业绩超预期>>
01-23 16:01
